Treatment for TTR amyloidosis + Treatment for TTR amyloidosis
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin (TTR) Amyloid Cardiomyopathy
Conditions
Transthyretin (TTR) Amyloid Cardiomyopathy
Trial Timeline
Oct 3, 2019 → Mar 27, 2025
NCT ID
NCT04108091About Treatment for TTR amyloidosis + Treatment for TTR amyloidosis
Treatment for TTR amyloidosis + Treatment for TTR amyloidosis is a pre-clinical stage product being developed by Pfizer for Transthyretin (TTR) Amyloid Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT04108091. Target conditions include Transthyretin (TTR) Amyloid Cardiomyopathy.
What happened to similar drugs?
3 of 19 similar drugs in Transthyretin (TTR) Amyloid Cardiomyopathy were approved
Approved (3) Terminated (0) Active (16)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04108091 | Pre-clinical | Completed |
Competing Products
20 competing products in Transthyretin (TTR) Amyloid Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 29 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 44 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 33 |
| Eplontersen | AstraZeneca | Phase 3 | 47 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 44 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 47 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 39 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 35 |
| Coramitug | Novo Nordisk | Phase 1 | 36 |
| Tafamidis | Pfizer | Pre-clinical | 26 |
| Tafamidis | Pfizer | Pre-clinical | 30 |
| tafamidis meglumine | Pfizer | Approved | 43 |
| Fx-1006A | Pfizer | Phase 2 | 35 |
| Tafamidis | Pfizer | Phase 3 | 40 |
| Tafamidis 61 milligrams | Pfizer | Pre-clinical | 26 |
| Vyndaqel | Pfizer | Pre-clinical | 26 |
| tafamidis | Pfizer | Phase 3 | 40 |
| Tafamidis | Pfizer | Approved | 43 |
| Tafamidis | Pfizer | Pre-clinical | 26 |
| Vyndamax (tafamidis 61mg) | Pfizer | Pre-clinical | 30 |